EU approval for AbbVie Inc.'s next-generation combination therapy Marivet to treat the hepatitis C virus (HCV), announced on the same day the firm reported its second quarter earnings, appears fortuitous as the new drug should offset declining revenues from the company's prior HCV product Viekira Pak and may give the firm another growth-driver alongside booming cancer drug Imbruvica.
AbbVie has a big hole to fill in the immediate future. Its anti-tumor necrosis factor agent Humira (adalimumab) has held on as the company's, and the industry's, top-selling product for years. Humira posted global sales of $4.72bn during the second quarter, up 15% from a year ago. That included $3.2bn in the US, up 18%, and $1.52bn ex-US, up 9%
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?